Table 1.
Characteristics of 17 patients treated with current RTSEI technique.
| Age/sex | Diagnosis/stage | Prior/local RT | Dose/fx | Side effects | Response |
|---|---|---|---|---|---|
| 77/F | NHL blastic NK-cell type | No | 30 Gy/15 fx | Hematologic toxicity | GPR |
| 43/M | CTCL CD8+ | Yes | 36 Gy/18 fx | Gr 3 dermatitis, blistering of hands and feet | GPR |
| 72/M | Follicular lymphoma | No | 30.6 Gy/17 fx | None | CR |
| 75/M | MF stage IIB T3 N1 | Yes | 24 Gy/12 fx | Gr 3 dermatitis, swelling and blistering of hands and feet. Discontinued RTSEI early b/c of toxicity | CR |
| 74/M | CTCL, non MF | No | 32 Gy/16 fx | Gr 3 dermatitis | CR |
| 64/M | MF stage IIB T3 N0 | No | 16 Gy/8 fx | None. Discontinued RTSEI early b/c of deteriorating general condition | NR |
| 68/M | CLL | No | 4 Gy/2 fx | None | PD |
| 73/M | MF stage IVA T4 N3 | No | 36 Gy/20 fx | Pain and swelling of feet | NR |
| 67/F | MF stage IIA T2 N1 | No | 36 Gy/18 fx | Gr 2 dermatitis | GPR |
| 70/F | MF stage IA T1 N0 | No | 36 Gy/18 fx | Gr 2 dermatitis, swelling of hands and feet | Unknown, no follow up |
| 81/M | AML, lymphoma cutis | No | 12 Gy/5 fx | None | Unknown, no follow up |
| 43/F | HTLV-1 T-cell lymphoma | No | 5 Gy/2 fx | None | NR |
| 69/F | CTCL | Yes | 29 Gy/15 fx | Gr 2 dermatitis | GPR |
| 69/F | MALT lymphoma | Yes | 12 Gy/3 fx | None | |
| 66/M | MF stage IIB T3 N0 | Yes | 36 Gy/18 fx | Gr 3 dermatitis, swelling of hands and feet | CR |
| 25/F | MF stage IIB T3 Nx | Yes | 30.6 Gy/17 fx | Gr 2 dermatitis | CR |
| 64/M | MF stage IIB T3 N0 | Yes | 36 Gy/20 fx | Gr 3 dermatitis, swelling of hands and feet | CR |
GPR: good partial response, CR: complete response, NR no response, PD: progressive disease.